NCCS Letter to HHS Highlights “Deep Reservations” Concerning Massachusetts 1115 Waiver
Read the full letter embedded below or download the letter in PDF format.
Your generous year-end donation will be matched $1 for $1 DONATE
Cancer care is often combination therapy incorporating drugs from different drug classes or multiple drugs in a class. In addition, cancer treatment is increasingly targeted according to the patient’s individual profile, often established through molecular testing. An individual patient may receive a clinical benefit from one drug in a class and not another, and a closed formulary may not be responsive to these individual needs. For some cancer patients, the management of the side effects of cancer treatment poses serious medication challenges. We are concerned that the closed formulary proposed by the Commonwealth for MassHealth patients will make it more difficult – if not impossible – for cancer patients to receive the drugs necessary for appropriate treatment therapies for those enrolled in MassHealth.
Read the full letter embedded below or download the letter in PDF format.
"*" indicates required fields
"*" indicates required fields
Founder
Northeast Regional Cancer Institute
“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”
—Karen M. Saunders
President, Northeast Regional Cancer Institute